Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
Thamm D, Vail D, Post G, Fan T, Phillips B, Axiak‐Bechtel S, Elmslie R, Klein M, Ruslander D. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma. Journal Of Veterinary Internal Medicine 2017, 31: 872-878. PMID: 28370378, PMCID: PMC5435064, DOI: 10.1111/jvim.14700.Peer-Reviewed Original ResearchConceptsProgression-free intervalMulticentric lymphomaComplete responseOverall median progression-free intervalMedian progression-free intervalMulticenter prospective clinical trialSubstantial single-agent activityAdverse effect profileAssessment of remissionMost adverse eventsProspective clinical trialsSingle-agent activityLong-term outcomesOverall response rateCanine multicentric lymphomaDermatologic AEsHematologic AEsClinicopathological evaluationAdverse eventsChemotherapy combinationsCombination chemotherapyTreatment visitsUntreated lymphomaEffect profilePulmonary fibrosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply